IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 5:30 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 5:30 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients
by Zacks Equity Research
Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.
Here's Why You Should Retain CONMED (CNMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics
by Zacks Equity Research
NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.
NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone
by Zacks Equity Research
NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.
Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Reasons to Hold on to AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
SmileDirectClub (SDC) Struggles With New Markets, High Debt
by Zacks Equity Research
SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.
Stryker (SYK) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
by Zacks Equity Research
TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
by Zacks Equity Research
Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.
Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI
by Zacks Equity Research
Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.
Omnicell (OMCL) Opens New Software Development Center in India
by Zacks Equity Research
Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.
Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How
by Zacks Equity Research
Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.
Here's Why You Should Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.
Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.
Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available
by Zacks Equity Research
In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.
Thermo Fisher (TMO) Gains Government Contract for Pipette Tip
by Zacks Equity Research
Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.
Hold Petco (WOOF) as It Rides on Continued Demand for Pet Care
by Sapna Bagaria
Petco (WOOF) by dint of its wide product and services portfolio, omni-channel presence and strategic initiatives is well poised to cash in on the expanding petcare industry.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials
by Zacks Equity Research
Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency
by Zacks Equity Research
BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.
4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip
by Urmimala Biswas
Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.